Kinaxis Launches Tariff Response Solution to Help Supply Chains Adapt to Disruption with Confidence
17.4.2025 20:30:00 EEST | Business Wire | Press release
As ongoing tariff pressures and trade uncertainty continue to reshape global supply chains, Kinaxis® (TSX:KXS), the leader in real-time supply chain orchestration, today launched Kinaxis Tariff Response - a new offering that helps companies simulate tariff exposure, run strategic scenarios, and make data-informed decisions quickly.
Built on the company’s AI-powered Maestro™ platform and delivered by Kinaxis supply chain experts, the service can be live in as few as 21 days, giving planners access to tariff modeling without the cost or complexity of building it internally. The solution meets rising demand for scenario planning - providing a faster, more accessible way for companies to shift from reactive firefighting to proactive orchestration.
While AI-powered what-if scenario planning has long been a core capability of Maestro, Kinaxis Tariff Response builds on that foundation with a focused solution for trade disruption. It combines tariff-specific inputs, sourcing logic, pricing levers, and demand modeling so companies can assess margin risk, test strategies, and evaluate trade-offs in seconds, not days or weeks.
“We’re already using Maestro scenario planning to model the impact of disruptions across our supply chain including tariffs and trade compliance policies,” said Colton Porter, manager, supply chain planning systems at furniture manufacturing and design company MillerKnoll. “It helps us evaluate sourcing options, anticipate risks, and align our team's strategy before those changes affect our margins or customer delivery commitments.”
“Global supply chains aren’t operating by the old rules anymore,” saidMark Morgan, president of global commercial operations at Kinaxis. “Tariffs are hitting faster, with broader consequences, and our data shows just how disruptive they’ve become. When trade policies shift overnight, companies need more than spreadsheets. With Kinaxis Tariff Response, they get visibility into cost, demand, and sourcing implications in real time, giving them the confidence to act with speed and precision.”
Supply chain data surging
Many Kinaxis customers already rely on Maestro’s scenario planning to stay ahead of supply chain disruptions. Over the past year, usage spiked significantly around key tariff discussions, showing how companies are turning to simulation to evaluate risks and respond faster:
- 124% scenario usage spike after the June 2024 presidential debate that first mentioned tariffs
- 112% increase following the January 2025 White House tariff memo
- 15% month-over-month rise ahead of the April 2 tariff announcements
- 24% increase in scenario planning usage quarter-over-quarter (Q1 2025 vs Q4 2024), with automotive, oil & gas, and consumer packaged goods leading the surge in anticipatory orchestration
- 4.5x daily activity in the auto sector alone during the final week of March 2025.
For more information about Kinaxis Tariff Response, please visit our website.
About Kinaxis
Kinaxis is a global leader in modern supply chain orchestration, powering complex global supply chains and supporting the people who manage them, in service of humanity. Our powerful, AI-infused supply chain orchestration platform, Maestro™ , combines proprietary technologies and techniques that provide full transparency and agility across the entire supply chain — from multi-year strategic planning to last-mile delivery. We are trusted by renowned global brands to provide the agility and predictability needed to navigate today’s volatility and disruption. For more news and information, please visit kinaxis.com or follow us on LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250417898161/en/
Contacts
Media Relations
Matt Tatham | Kinaxis
Mtatham@kinaxis.com
+1 917 446 7227
Investor Relations
Rick Wadsworth | Kinaxis
rwadsworth@kinaxis.com
+1 613-907-7613
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom